<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03998293</url>
  </required_header>
  <id_info>
    <org_study_id>19-003525</org_study_id>
    <secondary_id>R01DK078645</secondary_id>
    <nct_id>NCT03998293</nct_id>
  </id_info>
  <brief_title>Direct Measurement of Proinsulin Clearance in Humans</brief_title>
  <official_title>Direct Measurement of Proinsulin Clearance in Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Researchers are trying to determine how quickly proinsulin is cleared from the circulation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      proinsulin clearance is necessary to determine the rate of secretion into the circulation
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proinsulin Clearance</measure>
    <time_frame>through study completion, each study will take an average of 8 hours</time_frame>
    <description>The half-life of proinsulin in a given individual</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proinsulin Distribution</measure>
    <time_frame>through study completion, each study will take an average of 8 hours</time_frame>
    <description>The volume of distribution of proinsulin in a given individual</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>proinsulin clearance</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>all participants will be studied once where somatostatin will be used to block endogenous insulin secretion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Somatostatin</intervention_name>
    <description>infused to block endogenous insulin secretion over a 4 hour period</description>
    <arm_group_label>proinsulin clearance</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Weight-stable, non-diabetic subjects from Biobank participants at Mayo Clinic,
             Rochester

        Exclusion Criteria:

          -  Age &lt; 25 or &gt; 65 years (to avoid studying subjects who could have latent type 1
             diabetes, or the effects of age extremes in subjects with normal or impaired fasting
             glucose).

          -  HbA1c â‰¥ 6.5%

          -  Use of glucose-lowering agents.

          -  For female subjects: positive pregnancy test at the time of enrollment or study

          -  History of prior upper abdominal surgery such as adjustable gastric banding,
             pyloroplasty and vagotomy.

          -  Active systemic illness or malignancy.

          -  Symptomatic macrovascular or microvascular disease.

          -  Hormone replacement therapy &gt;0.625 mg premarin daily
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adrian Vella</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paula Giesler, RN</last_name>
    <phone>507-255-8345</phone>
    <email>giesler.paula@mayo.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 24, 2019</study_first_submitted>
  <study_first_submitted_qc>June 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 26, 2019</study_first_posted>
  <last_update_submitted>June 25, 2020</last_update_submitted>
  <last_update_submitted_qc>June 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Adrian Vella</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Somatostatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

